Aclarion, Inc. ACON
1.63 USD +0.09 (+5.57%)
Nov 6, 2026, 11:06 AM EST
1.61 Day range 1.64
1.54 52-week range 9.36
- YTD
- -64.57%
- 1 year
- -78.30%
- Market cap
- 4.70M
- Revenue (ttm)
- 53.95K
- EPS (ttm)
- -7.38
- Shares out
- 10.44M
- Forward P/E
- -0.24
- YTD return
- -64.57%
- 1-year return
- -78.30%
- Volume
- 12.55K
- Avg volume
- 44.23K
- Open
- 1.64
- Previous close
- 1.54
- Day's range
- 1.61 – 1.64
- 52-week range
- 1.54 – 9.36
- Beta
- 0.40
- Analysts
- Buy
- Price target
- 1.30 (-20.2%)
- Earnings date
- Aug 14, 2024
5D -0.44 (-22.00%)
Key statistics
- Enterprise value
- 960.52K
- PEG ratio
- 0.00
- Price / sales
- 24.77
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -35.70%
- Free cash flow
- -3.94M
- Total cash
- 1.22M
- Total debt
- 777.09K
- Return on equity
- -714.18%
- Short % of float
- 4.28%
- 50-day average
- 0.1701
- 200-day average
- 0.250115
Analyst view
Consensus: buy
Buy
Price target (mean) 1.30
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.15.
Financials — quick view
ACON Revenue — quarterly 25.21K
ACON Net income — quarterly -2.75M
ACON EPS — quarterly -1.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.18 | -0.15 | +0.03 | +16.67% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.15 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.44 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Maxim Group | down | Buy | Hold |
| Nov 27, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 26, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 29, 2024 | Ascendiant Capital | init | — | Buy |
About Aclarion, Inc.
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- aclarion.com
News
Aclarion Publishes CEO Letter; Notes Q3 Scan Volumes Up 85% YoY And Up 117% YtD 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's After-Market Session - 12 Health Care Stocks Moving In Tuesday's After-Market Session
Aclarion Announces University Of Arizona College Of Medicine - Phoenix As New Clinical Site In Its CLARITY Trial 
Aclarion Says USPTO Issues Notice Of Allowance For U.S. Patent Application Titled Multi-Voxel Prescription For Lumbar Disc Evaluation 
Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY Trial - Aclarion Launches Market Access Program In Partnership With PRIA Healthcare
Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject It 
Aclarion Partners With Institute of Neuro Innovation on Back Pain Technology
Your note
Sign in to keep a note on ACON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LORBIECKI JOHN PAUL | Chief Financial Officer | Purchase | Dec 28, 2022 | 22,404 |
| NESS BRENT | Chief Executive Officer | Purchase | Dec 28, 2022 | 19,500 |
| THRAMANN JEFFREY JOHN | Officer and Director | Purchase | Feb 15, 2023 | 1 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Captrust Financial Advisors | 2.05% | 214,029 | 27.39K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.47% | 49,301 | 6.31K | Sep 29, 2024 |
| UBS Group AG | 0.38% | 39,971 | 5.12K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.32% | 33,892 | 4.34K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.14% | 14,153 | 1.81K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.12% | 12,239 | 1.57K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 33,266 | 4.26K | Oct 30, 2024 |